Learn What the Leading Players in the Orphan Drug Market are Doing via Detailed Analyses of their Pipelines

Dublin (PRWEB) January 27, 2006 -- Research and Markets (http://www.researchandmarkets.com/reports/c31532) has announced the addition of Orphan Drugs Pipeline Analysis: Wider Incentives Encourage Orphan Drug R&D to their offering

This report examines the pipeline of drugs in development under the guidance of orphan drug legislation in the major markets of the United States, Europe and Japan. Each of these markets has orphan drug legislation with different provisions, and we compare and contrast these regulatory factors. The contrasting requirements and different time frames in which this legislation has been enacted has also resulted in considerable differences in the numbers of designated and approved orphan drugs within each market.

More than 6,000 rare diseases could potentially be designated as eligible for development of orphan drugs. However, this report focuses on diseases that have attracted the most attention from orphan drug developers - namely, genetic diseases, uncommon autoimmune diseases, and cancer. It also discusses which cancers are potentially eligible for gaining orphan drug designation. Given the large number of orphan drugs targeting various cancers, an entire section of this report is devoted solely to cancer therapies. Other orphan drugs in this report are grouped according to their primary mode of action: enzymes and enzyme inhibitors, hormones, gene therapies, gene modulators, monoclonal antibodies, and receptor and ion channel modulators.

The report then profiles companies that are active in the development of orphan drugs. It separately profiles the small number of orphan drug specialist companies and the larger number of biotechnology companies for whom orphan drug development constitutes a significant proportion of their current pipeline. Finally, it discusses how the orphan drug market is likely to evolve over the next ten years by considering the influence of such factors as patent issues, pharmacogenomics, and the reimbursement environment.

For more information visit http://www.researchandmarkets.com/reports/c31532

Source: Decision Resources

Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

###